- Conditions
- Hemophilia A
- Interventions
- PLASMA DERIVED Factor VIII, Recombinant FVIII
- Drug
- Lead sponsor
- Fondazione Angelo Bianchi Bonomi
- Other
- Eligibility
- 1 Minute to 6 Years · Male only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prevent Bleeding in Major Surgery
- Interventions
- human VWF/FVIII concentrate
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Chapel Hill, North Carolina • Milwaukee, Wisconsin
- Conditions
- Von Willebrand Diseases
- Interventions
- Wilate
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia A, Congenital
- Interventions
- Alphanate
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
- Conditions
- Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
- Interventions
- Blood coagulation Factor VIII and vWF, human
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Haemophilia A
- Interventions
- Not listed
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • New Orleans, Louisiana • St Louis, Missouri + 2 more
- Conditions
- Hemophilia A With Inhibitor, Hemophilia A
- Interventions
- Wilate
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Sacramento, California • San Diego, California • New Orleans, Louisiana
- Conditions
- Severe Hemophilia A
- Interventions
- VWF/FVIII concentrates
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Von Willebrand Disease
- Interventions
- Wilate
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hemophilia A
- Interventions
- Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Von Willebrand Disease
- Interventions
- Patients using Wilate as standard of care
- Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more
- Conditions
- Von Willebrand Diseases
- Interventions
- Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more